



Simposio Internacional: Enfermedades neuromusculares: es el tiempo para el tratamiento

International Symposium: Neuromuscular diseases: It's time for treatment

Madrid, 15 y 16 de noviembre de 2012

Madrid, November 15-16, 2012

The system *ubiquitin-proteasoma*

Madeleine Durbeej

Laminin $\alpha 2$ chain mutations cause congenital muscular dystrophy with dysmyelination neuropathy (MDC1A). As muscle atrophy is a significant characteristic of MDC1A, we investigated if increased protein degradation is a feature of laminin $\alpha 2$ chain deficient muscles. Indeed, the ubiquitin-proteasome system, which plays a major role in muscle wasting, appeared overactive in MDC1A. Also, the autophagy-lysosome pathway, which is the other major system involved in degradation of proteins and organelles, was dysregulated in MDC1A. Moreover, separate treatments with a proteasome inhibitor (MG-132) and an autophagy inhibitor (3-methyladenine) significantly improved the dystrophic dy^{3K}/dy^{3K} phenotype. These findings indicate that increased activity of the ubiquitin-proteasome system and enhanced autophagic activity are pathogenic in MDC1A and that proteasome and autophagy inhibition, respectively, holds a promising therapeutic potential in the treatment of MDC1A.

*Todos los derechos de propiedad intelectual son del autor. Queda prohibida la reproducción total o parcial de la obra sin autorización expresa del autor.

© FUNDACIÓN RAMÓN ARECES. Todos los derechos reservados.

**All intellectual property rights belong to the author. Total or partial reproduction of the work without express permission of the author is forbidden.*

© FUNDACIÓN RAMÓN ARECES. All rights reserved.